GW Pharmaceuticals plc (Nasdaq: GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of the previously announced underwritten public offering on the Nasdaq Global Market by GW of 2,400,000 American Depositary Shares (“ADSs”) and the full exercise by the underwriters of their option to purchase 360,000 additional ADSs from GW at a price to the public of $115.00 per ADS, raising gross proceeds of $317,400,000 (before deducting underwriting discounts, commissions and offering expenses).
Goldman Sachs & Co. LLC, Morgan Stanley, BofA Merrill Lynch and Cowen acted as joint book-running managers for the offering.
The ADSs described above were offered by GW pursuant to a shelf registration statement filed by GW with the Securities and Exchange Commission (“SEC”) that became automatically effective on April 17, 2017.
Read original release
Read More
GW Pharma Closes $317.4 Million Equity Offering
